The quarterly loss came in modestly better than the published consensus. EPS was a loss of $0.44, versus the published consensus of roughly $0.53 loss—a $0.09 beat. For a pre-revenue biotech, that is a useful but secondary positive: the investment case remains driven by bempikibart clinical and regulatory execution, not near-term operating earnings.
| Metric | Q2 2026 | Comparison / expectation |
|---|---|---|
| Net loss per share | ($0.44) | ($0.78) a year ago; published consensus roughly ($0.53) (Condensed Consolidated Statements of Operations) |
| Net loss | ($8.9M) | ($9.5M) a year ago (Condensed Consolidated Statements of Operations) |
| R&D expense | $4.3M | $5.2M a year ago; decline largely reflects the prior sale of ADX-097, partly offset by bempikibart work (Financial Results) |
| Cash at June 30 | $106.3M | $48.3M at year-end 2025; excludes the July financing proceeds (Condensed Consolidated Balance Sheets) |
| July public offering | $200.0M gross | Completed before this earnings release; not new information for this filing (Second Quarter 2026 and Recent Business Highlights) |
The important clinical update is confirmation, not a new catalyst. The filing repeats the July 13 Week-36 SIGNAL-AA results: 35.3% mean SALT-score reduction in the modified intent-to-treat group and a 30.3% SALT-20 response rate across all 33 enrolled patients, with no new safety signal reported (Second Quarter 2026 and Recent Business Highlights). Those data had already reset expectations in July, so their reappearance here does not add a fresh efficacy surprise.
The development timetable held, which removes a potential concern but does not accelerate the story. Management still expects to begin a registration-directed study in the first half of 2027, subject to regulatory discussions later in 2026; additional Week-36 detail and initial Week-52 off-drug findings remain slated for a medical meeting in the second half of 2026 (Second Quarter 2026 and Recent Business Highlights). In other words, the next material proof point is still durability data, not this earnings release.
Funding risk has been pushed beyond the planned pivotal readout, at the cost of already-known dilution. Combining June-end cash with the completed $200.0M July equity offering, management says it can fund operations through topline results from the planned registration-directed program (Financial Results; Second Quarter 2026 and Recent Business Highlights). That strengthens the ability to execute the program without an imminent financing need, but the financing itself was public before this report and increased the share base; it is a balance-sheet confirmation rather than incremental news.
Read the original 8-K on SEC EDGAR ↗